References

Abtahi J, Agholme F, Aspenberg P. 2013. Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. Int J Oral Maxillofac Surg. 42:632–636.

Abtahi J, Agholme F, Sandberg O, Aspenberg P. 2012. Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed: no primary necrosis in unexposed bone. J Oral Pathol Med. 41:494–499.

Almazrooa SA, Woo SB. 2009. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc. 140:864–875.

Amgen. 2010a. Highlights of prescribing information: Prolia (denosumab) injection, for subcutaneous use. Thousand Oaks (CA) [accessed 2015 Jan 19]. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf.

Amgen. 2010b. Highlights of prescribing information: Xgeva (denosumab) injection, for subcutaneous use. Thousand Oaks (CA) [accessed 2015 Jan 19]. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf.

Barbeau J, Deslauriers N. 1989. Phenotypic and functional analysis of oral mucosal macrophages. Reg Immunol. 2:285–293.

Baron R, Ferrari S, Russell RG. 2011. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48:677–692.

Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, Bettini G, Di Fede O, Oteri G, et al. 2014. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg. 52:603–608.

Belibasakis GN, Bostanci N, Hashim A, Johansson A, Aduse-Opoku J, Curtis MA, Hughes FJ. 2007. Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by *Porphyromonas gingivalis*: a putative role of the Arg-gingipains. Microb Pathog. 43:46–53.

Bonacina R, Mariani U, Villa F, Villa A. 2011. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc. 77:b147.

Bonnet N, Lesclous P, Saffar JL, Ferrari S. 2013. Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice. PLoS One. 8(3):e58726.

Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature. 423(6937):337–342.

Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, Piva S, Dimaiuta M, La Verde N. 2015. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab. 33:119–24.

Chang MK, Raggatt LJ, Alexander KA, Kuliwaba JS, Fazzalari NL, Schroder K, Maylin ER, Ripoll VM, Hume DA, Pettit AR. 2008. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 181:1232–1244.

Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. 2011. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone. 49:710–716.

Downloaded from jdr.sagepub.com at UNIV TORONTO on June 26, 2015 For personal use only. No other uses without permission.

© International & American Associations for Dental Research 2015

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. 2008. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 42:848–860.

de Ceulaer J, Tacconelli E, Vandecasteele SJ. 2014. Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? Eur J Clin Microbiol Infect Dis. 33:1873–1880.

Epstein MS, Ephros HD, Epstein JB. 2013. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol. 116(6):e437–e442.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P. 2002. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538–6544.

Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. 2010. Development of monocytes, macrophages, and dendritic cells. Science. 327(5966):656–661.

Ginhoux F, Jung S. 2014. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 14:392–404.

Han X, Lin X, Seliger AR, Eastcott J, Kawai T, Taubman MA. 2009. Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. Oral Microbiol Immunol. 24:190–196.

Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ. 2007. Actinomycosis of the jaws: histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 451:1009–1017.

Hoefert S, Schmitz I, Tannapfel A, Eufinger H. 2010. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig. 14:271–284.

Hoefert S, Schmitz I, Weichert F, Gaspar M, Eufinger H. 2014. Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases [published online 24 Jun 2014]. Clin Oral Investig.

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, et al. 2008. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 23:826–836.

Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, Garrett N, Adams JS, Nishimura I. 2010. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res. 25:1337–1349.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, et al; International Task Force on Osteonecrosis of the Jaw. 2014. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 30:3–23.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al; American Society for Bone and Mineral Research. 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 22:1479–1491.

López-Jornet P, Camacho-Alonso F, Martínez-Canovas A, Molina-Miñano F, Gómez-García F, Vicente-Ortega V. 2011. Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. J Oral Maxillofac Surg. 69:2488–2493.

Marx RE. 2003. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 61:1115–1117.

McLeod NM, Patel V, Kusanale A, Rogers SN, Brennan PA. 2011. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg. 49:335–342.

Migliorati CA, Epstein JB, Abt E, Berenson JR. 2011. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol. 7:34–42.

Migliorati CA, Schubert MM, Peterson DE. 2009. Bisphosphonate osteonecrosis (BON): unanswered questions and research possibilities. Rev Recent Clin Trials. 4:99–109.

Naik NH, Russo TA. 2009. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis. 49:1729–1732.

Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. 1996. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 64:2371–2380.

Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA. 2011. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112:195–202.

Oteri G, Bramanti E, Nigrone V, Cicciù M. 2013. Decayed, missing, and filled teeth index and periodontal health in osteoporotic patients affected by BRONJ: an observational study. J Osteoporos. 2013. Article 231289.

Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, Stürzenbaum SR, von Tresckow E, Kolk A, Ehrenfeld M, et al. 2010. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg. 68:1158–1161.

Pazianas M. 2011. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 103:232–240.

Pazianas M, Cooper C, Ebetino FH, Russell RG. 2010. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 6:325–343.

Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. 2007. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 29:1548–1558.

Reid IR, Cornish J. 2012. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 8:90–96.

Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E. 2009. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: the experience of the National Cancer Institute of Milan. Ann Oncol. 20:137–145.

Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Koerdt S, Otto S, Pautke C. 2014. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. Br J Oral Maxillofac Surg. 52:308–313.

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. 2009. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg. 67 Suppl (5):2–12.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. 2014. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J Oral Maxillofac Surg. 72:1938–1956.

Ruggiero SL, Drew SJ. 2007. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 86:1013–1021.

Russell RG, Watts NB, Ebetino FH, Rogers MJ. 2008. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 19:733–759.

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, et al. 2012. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 23:1341–1347.

Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, et al. 2003. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 9:2893–2897.

Toulis KA, Anastasilakis AD. 2010. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int. 21:1963–1964.

Vermeer JA, Jansen ID, Marthi M, Coxon FP, McKenna CE, Sun S, de Vries TJ, Everts V. 2013. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors. Bone. 57:242–251.

Wimalawansa SJ. 2008. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 7:491–512.

Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR. 2002. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 302:1055–1061.

Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C. 2011. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 15:105–111.

Downloaded from jdr.sagepub.com at UNIV TORONTO on June 26, 2015 For personal use only. No other uses without permission.

© International & American Associations for Dental Research 2015